沙库巴曲缬沙坦与厄贝沙坦治疗慢性心力衰竭的疗效对比

Comparison of curative effect of sacubitril valsartan and irbesartan in the treatment of chronic heart failure

目的 比较沙库巴曲缬沙坦与厄贝沙坦治疗慢性心力衰竭的临床疗效。方法 选取2021年安顺市西秀区人民医院收治的慢性心力衰竭患者90例,采用随机数字表法分为厄贝沙坦组与缬沙坦组,每组45例。患者均接受常规治疗,基于此,厄贝沙坦组患者采用厄贝沙坦治疗,缬沙坦组患者采用沙库巴曲缬沙坦治疗,2组均持续治疗8周。比较2组临床疗效、治疗前及治疗8周后心功能相关指标[6 min步行距离、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、血清N末端脑钠肽前体(NT-proBNP)水平]及不良反应发生率。结果 缬沙坦组总有效率为93.33%,高于厄贝沙坦组的77.78%(χ^(2)=4.406,P=0.036)。治疗8周后,2组6 min步行距离较治疗前延长,LVEF较治疗前升高,LVEDD、LVESD较治疗前缩小,血清NT-proBNP水平较治疗前降低,且缬沙坦组上述指标优于厄贝沙坦组(P<0.05或P<0.01)。2组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 沙库巴曲缬沙坦治疗慢性心力衰竭患者的疗效优于厄贝沙坦,能更有效地改善患者心功能,提高运动耐力,且具有一定的安全性。

Objective To compare the clinical effect of sacubitril valsartan and irbesartan for patients with chronic heart failure. Methods A total of 90 cases of patients with chronic heart failure were selected in 2021 in Anshun Xixiu District People′s Hospital, and they were divided into the irbesartan group and the valsartan group by random number table method, with 45 cases in each group. atients were given basic treatment, and patients in the irbesartan group were treated with irbesartan, and patients in the valsartan group were treated with sacubitril valsartan, both groups were treated for 8 weeks. Clinical efficacy, cardiac function indexes(6 min walking distance, LVEF, LVEDD, LVESD, serum NT-proBNP level) before treatment and at 8 weeks after treatment and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of the valsartan group was 93.33%, which was higher than 77.78% of the irbesartan group(χ^(2)=4.406, P=0.036). At 8 weeks after treatment, 6 min walking distance of the two groups was longer than that before treatment, LVEF was higher than that before treatment, LVEDD, LVESD were less than those before treatment, serum NT-proBNP level was lower than that before treatment, and those indexes of the valsartan group were better than irbesartan group(P<0.05 or P<0.01). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion For patients with chronic heart failure, the treatment effect of sacubitril valsartan is better than that of irbesartan, which can more effectively improve their cardiac function, promote exercise endurance, and with certain safety.